Abstract: The present disclosure relates to pharmaceutical compounds of the Formula (I), (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt or composition thereof. Also provided are methods of use of TRPML modulators for treating disorders, the modulators including compounds of the Formula (I), (Ia), (Ib), or (Ic). Such methods of use include treatment of ciliopathies.

Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Abstract: This disclosure relates to methods, systems and compositions for food coloring. Embodiments disclosed herein may include methods and systems for combining tea leaves and water to form a feed slurry; processing a feed slurry to at least partially remove a tea essence from the feed slurry, thereby obtaining a tea extract with a predetermined amount of one or more of an aroma or a flavor; and adjusting a color of the tea extract, thereby obtaining a coloring agent with a predetermined color-related feature, wherein the coloring agent is added in a predetermined amount to a food product to adjust a color of the food product. Embodiments may also including coloring compositions, which may include a dry tea extract, wherein an essence has been removed from the dry tea extract to a predetermined amount, and a color of the dry tea extract has been adjusted to have a predetermined color-related feature.

Abstract: The present disclosure relates to pharmaceutical compounds of the Formulas I, Ia, Ib, or Ic or a pharmaceutically acceptable salt or composition thereof. Also provided are methods of use of TRPML modulators for treating disorders, the modulators including compounds of the Formulas I, Ia, Ib, or Ic. Such methods of use include treatment of ciliopathies.

Abstract: The present patent application discloses the compounds according to Formula I shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.

Abstract: A fuel injector clamp has a clamp body extending between a fuel rail side and a cylinder head side. The fuel rail side has a bolt fixing surface extending in a first plane and a rail mounting surface extending in an oblique second plane relative to the first plane. The cylinder head side has a clamp mounting surface extending in a third plane parallel to the first plane. The clamp body defines a first bolt bore, a second bolt bore, and an injector pocket. The first bolt bore extends from the bolt fixing surface at the fuel rail side through the clamp body to the cylinder head side perpendicular to the bolt fixing surface and the clamp mounting surface. The second bolt bore extends from the rail mounting surface at the fuel rail side into the clamp body perpendicular to the rail mounting surface. The injector pocket extends through the clamp mounting surface perpendicularly through the clamp body to the rail mounting surface.

Abstract: The present disclosure relates to methods of treating a ciliopathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutical composition thereof, wherein the compound modulates a TRPML ion channel. The disclosure also relates to pharmaceutical compounds of Formula (III) and subformulas thereof, or a pharmaceutically acceptable salt or composition thereof, and methods of their use for modulating TRPML ion channels, and for treating disorders.

Abstract: The present patent application discloses the compounds according to Formula I shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. In some embodiments, the compounds are those of Table I or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO-sGC-cGMP pathway is desirable. Compounds useful in the methods of the invention are those of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The present disclosure relates to a pharmaceutical preparation for oral delivery of a therapeutic agent to the colon.

Abstract: The present patent application discloses the compounds according to Formula I shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.

Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Abstract: A polyelectrolyte-surfactant complex, a method of removing a toxic substance from contaminated soil or contaminated groundwater using a polyelectrolyte-surfactant complex and a method of making a polyelectrolyte-surfactant complex. The polyelectrolyte-surfactant complex is made from a complexated recombinant intrinsically disordered protein that has been electrostatically conjugated to an anionic surfactant to provide enhanced liquid-liquid phase separation properties.

Abstract: A method for transfecting microorganisms comprises inoculating a growth media consisting of at least one of sterile LB media and tryptic soy broth with microorganism cells (cells) consisting of at least one of E.coli (DH5?), C. lytica, or B. subtilus, Pichia pastoris; growing the cells at between 28-40° C. to achieve a desired cell density; harvesting the cells; adding a protein ionic liquid consisting of at least one of green fluorescent protein (GFP), ferritin, rabbit IgG antibodies, and photosystem II from spinach ionic liquid to the cells; suspending the cells in the protein ionic liquid; freezing the suspended cells between ?20 to ?212° C.; and removing at least 99% of water from the frozen suspended cells to make a cell powder. The cell powder may be reconstituted in Tris HCl buffer and mixed to obtain uniform cell suspension; and centrifuged to obtain cell pellet.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Abstract: Disclosed herein are non-alcoholic nitrogen infused beverages and method for producing such beverages. The processes described herein comprise producing a mixed gas beverage supported with a foaming agent. Liquid nitrogen and carbon dioxide are added to the beverage, with the addition of a foaming agent, such as soapbark extract. In some embodiments, this process provides a nitrogen infused beverage with foaming and cascading capabilities that are equivalent to a nitro experience delivered through a widget can, without the need for the widget or the use of nitrous oxide.

Abstract: A method for modifying the properties of balsa wood comprises infiltrating a protein ionic liquid comprising polymerized dopamine into delignified balsa wood. A method of making an optically active protective coating comprises mixing protein ionic liquid comprising polymerized dopamine with ethyl acetate-based or water-based nail polish. A method of making a thermoplastic having biological activity comprises melting a thermoplastic; and blending a protein ionic liquid with the thermoplastic; and cooling the thermoplastic protein ionic liquid blend to a solid state. The thermoplastic is a hot glue stick. The protein ionic liquid comprises antibodies, enzymes, or fluorescent proteins.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.